Rigel Pharmaceuticals Files 8-K Report
Ticker: RIGL · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, financial-statements, exhibits
Related Tickers: RIGL
TL;DR
Rigel Pharma filed a routine 8-K with SEC, mostly financial docs.
AI Summary
On December 9, 2024, Rigel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a significant event. No specific financial figures or new business developments were detailed in the provided excerpt.
Why It Matters
This filing serves as a standard disclosure for Rigel Pharmaceuticals, Inc., providing updates on financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing appears to be a standard procedural update with no immediate indication of significant financial changes or operational risks.
Key Players & Entities
- RIGEL PHARMACEUTICALS, INC. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 611 Gateway Boulevard Suite 900 (address) — Principal executive offices
- South San Francisco (location) — City of principal executive offices
- CA (state) — State of principal executive offices
- 94080 (zip_code) — Zip code of principal executive offices
- 650-624-1100 (phone_number) — Registrant's telephone number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 9, 2024.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is RIGEL PHARMACEUTICALS, INC.
In which state or other jurisdiction was Rigel Pharmaceuticals, Inc. incorporated?
Rigel Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address of Rigel Pharmaceuticals, Inc.?
The principal executive office address is 611 Gateway Boulevard Suite 900, South San Francisco, CA 94080.
What is the registrant's telephone number, including area code?
The registrant's telephone number is (650) 624-1100.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-12-09 16:15:15
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar
Filing Documents
- tm2430504d1_8k.htm (8-K) — 24KB
- tm2430504d1_ex99-1.htm (EX-99.1) — 20KB
- 0001104659-24-126758.txt ( ) — 220KB
- rigl-20241209.xsd (EX-101.SCH) — 3KB
- rigl-20241209_lab.xml (EX-101.LAB) — 33KB
- rigl-20241209_pre.xml (EX-101.PRE) — 22KB
- tm2430504d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On December 9, 2024, Rigel Pharmaceuticals, Inc. (" Rigel ") announced certain data from its ongoing Phase 1b clinical trial evaluating R289 in lower-risk myelodysplastic syndrome. A copy of Rigel's press release, titled "Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition," is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated December 9, 2024, titled "Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 9, 2024 RIGEL PHARMACEUTICALS, INC. By: /s/ Raymond J. Furey Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary